Last reviewed · How we verify
BIA 3-202
At a glance
| Generic name | BIA 3-202 |
|---|---|
| Also known as | Nebicapone |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin (PHASE1)
- Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon (PHASE2)
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg (PHASE1)
- Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients (PHASE2)
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide (PHASE1)
- Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa (PHASE1)
- Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202 (PHASE1)
- Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIA 3-202 CI brief — competitive landscape report
- BIA 3-202 updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI